Arcus Biosciences, Inc. Increase (Decrease) in Other Noncurrent Liabilities
Arcus Biosciences, Inc. (RCUS) reported Increase (Decrease) in Other Noncurrent Liabilities of -$18.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities · last filed 2026-08-05
- Arcus Biosciences, Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2026-06-30 was -$2.00M, a 140.00% decline year-over-year.
- Arcus Biosciences, Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2026-03-31 was -$16.00M.
- Arcus Biosciences, Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2025-12-31 was -$4.00M, a 133.33% decline year-over-year.
- Arcus Biosciences, Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2025-09-30 was $24.00M, a 9.09% increase year-over-year.
- Arcus Biosciences, Inc. increase (decrease) in other noncurrent liabilities for fiscal 2025 was $8.00M, a 68.00% decline from fiscal 2024.
- Arcus Biosciences, Inc. increase (decrease) in other noncurrent liabilities for fiscal 2024 was $25.00M.
- Arcus Biosciences, Inc. increase (decrease) in other noncurrent liabilities for fiscal 2023 was -$3.00M, a 114.29% decline from fiscal 2022.
- Arcus Biosciences, Inc. increase (decrease) in other noncurrent liabilities for fiscal 2022 was $21.00M, a 23.53% increase from fiscal 2021.
| Period end | Increase (Decrease) in Other Noncurrent Liabilities 3 month | Increase (Decrease) in Other Noncurrent Liabilities 3 month as first filed | Increase (Decrease) in Other Noncurrent Liabilities 6 month | Increase (Decrease) in Other Noncurrent Liabilities 9 month | Increase (Decrease) in Other Noncurrent Liabilities 9 month as first filed | Increase (Decrease) in Other Noncurrent Liabilities 12 month | Increase (Decrease) in Other Noncurrent Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$18.00M 10-Q · filed 2026-08-05 | -$22.00M derived: sum of 3 quarters · filed 2026-08-05 | $2.00M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2026-03-31 | -$16.00M 10-Q · filed 2026-05-05 | -$20.00M derived: sum of 2 quarters · filed 2026-05-05 | $4.00M derived: sum of 3 quarters · filed 2026-05-05 | $9.00M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-12-31 | -$4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $20.00M derived: sum of 2 quarters · filed 2026-02-25 | $25.00M derived: sum of 3 quarters · filed 2026-08-05 | $8.00M 10-K · filed 2026-02-25 | |||
| 2025-09-30 | $24.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $29.00M derived: sum of 2 quarters · filed 2026-08-05 | $12.00M 10-Q · filed 2025-10-28 | $24.00M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-06-30 | $5.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$12.00M 10-Q · filed 2026-08-05 | $0.00 derived: sum of 3 quarters · filed 2026-08-05 | $22.00M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-03-31 | -$17.00M 10-Q · filed 2026-05-05 | -$5.00M derived: sum of 2 quarters · filed 2026-05-05 | $17.00M derived: sum of 3 quarters · filed 2026-05-05 | $20.00M derived: sum of 4 quarters · filed 2026-05-05 | |||
| 2024-12-31 | $12.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $34.00M derived: sum of 2 quarters · filed 2026-02-25 | $37.00M derived: sum of 3 quarters · filed 2026-02-25 | $25.00M 10-K · filed 2026-02-25 | |||
| 2024-09-30 | $22.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $25.00M derived: sum of 2 quarters · filed 2025-10-28 | $13.00M 10-Q · filed 2025-10-28 | $6.00M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2024-06-30 | $3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$9.00M 10-Q · filed 2025-08-06 | -$16.00M derived: sum of 3 quarters · filed 2026-02-25 | $1.00M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2024-03-31 | -$12.00M 10-Q · filed 2025-05-06 | -$19.00M derived: sum of 2 quarters · filed 2026-02-25 | -$2.00M derived: sum of 3 quarters · filed 2026-02-25 | $6.00M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2023-12-31 | -$7.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $10.00M derived: sum of 2 quarters · filed 2026-02-25 | $18.00M derived: sum of 3 quarters · filed 2026-02-25 | -$3.00M 10-K · filed 2026-02-25 | |||
| 2023-09-30 | $17.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $25.00M derived: sum of 2 quarters · filed 2024-11-06 | $4.00M 10-Q · filed 2024-11-06 | $15.00M derived: sum of 4 quarters · filed 2025-02-25 | |||
| 2023-06-30 | $8.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$13.00M 10-Q · filed 2024-08-08 | -$2.00M derived: sum of 3 quarters · filed 2025-02-25 | $5.36M derived: sum of 4 quarters · filed 2025-02-25 | |||
| 2023-03-31 | -$21.00M 10-Q · filed 2024-05-08 | -$10.00M derived: sum of 2 quarters · filed 2025-02-25 | -$2.65M derived: sum of 3 quarters · filed 2025-02-25 | $1.00M derived: sum of 4 quarters · filed 2025-02-25 | |||
| 2022-12-31 | $11.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $18.36M derived: sum of 2 quarters · filed 2025-02-25 | $22.00M derived: sum of 3 quarters · filed 2025-02-25 | $21.00M 10-K · filed 2025-02-25 | |||
| 2022-09-30 | $7.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $11.00M derived: sum of 2 quarters · filed 2023-11-07 | $10.00M 10-Q · filed 2023-11-07 | $3.71M 10-Q · filed 2022-11-02 | $27.00M derived: sum of 4 quarters · filed 2024-02-21 | ||
| 2022-06-30 | $3.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $2.65M 10-Q · filed 2022-08-03 | $19.65M derived: sum of 3 quarters · filed 2024-02-21 | $19.65M derived: sum of 4 quarters · filed 2024-02-21 | |||
| 2022-03-31 | -$1.00M 10-Q · filed 2023-05-09 | $2.27M 10-Q · filed 2022-05-09 | $16.00M derived: sum of 2 quarters · filed 2024-02-21 | $16.00M derived: sum of 3 quarters · filed 2024-02-21 | $16.00M derived: sum of 4 quarters · filed 2024-02-21 | ||
| 2021-12-31 | $17.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $17.00M derived: sum of 2 quarters · filed 2024-02-21 | $17.00M derived: sum of 3 quarters · filed 2024-02-21 | $17.00M 10-K · filed 2024-02-21 | -$498.00K 10-K · filed 2022-02-23 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $0.00 derived: sum of 2 quarters · filed 2022-11-02 | -$2.00K 10-Q · filed 2022-11-02 | $10.03M derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$2.00K 10-Q · filed 2022-08-03 | $10.03M derived: sum of 3 quarters · filed 2023-02-28 | $17.69M derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2021-03-31 | -$2.00K 10-Q · filed 2022-05-09 | $10.03M derived: sum of 2 quarters · filed 2023-02-28 | $17.69M derived: sum of 3 quarters · filed 2023-02-28 | ||||
| 2020-12-31 | $10.03M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $17.69M derived: sum of 2 quarters · filed 2023-02-28 | $18.00M 10-K · filed 2023-02-28 | $10.20M 10-K · filed 2021-02-25 | |||
| 2020-09-30 | $7.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $7.97M 10-Q · filed 2021-11-08 | |||||
| 2020-06-30 | $310.00K 10-Q · filed 2021-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |